P-270: EFFECTIVENESSS OF MICRO CME AT IMPROVING CLINICAL KNOWLEDGE AND COMPETENCE RELATED TO BCMA-TARGETED THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

Introduction: With BCMA-targeted therapies available for multiple myeloma (MM), it is important that physicians are knowledgeable and competent in how to use these agents. This study aimed to determine whether online continuing medical education consisting of micro-chapters could improve the knowledge, competence, and confidence of hematologists/oncologists (hem/oncs) in managing patients with relapsed/refractory MM who are candidates for BCMA-targeted therapy.

Methods: The educational initiative consisted of a collection of five online video-based micro-CME chapters, presented by three respected MM experts, allowing learners to choose the chapters for participation. The education effects were assessed using a repeated pairs pre-assessment/post-assessment study design, where individual participants served as their own control. McNemar’s tests (P <.05) determined statistical significance overall in level of mastery of the content (made at least 1 more decision correctly or improved confidence in their correct decisions from pre- to post-education). At the question level, a paired-analysis confidence-based assessment (CBA) measured changes in competence and confidence in learners’ pre/post responses to identify learners who are correct and confidence (mastery), correct but not confident (doubt), incorrect or confident (uninformed), and incorrect but confident (misinformed). 1 question was asked per micro chapter. Data were collected from 30/12/22 to 18/04/23.

Results: Data from 60 hem/oncs who completed the pre/post questions were included in the analysis. Improvements in percentage of correct decisions answered confidently were seen from pre- to post (36% vs 63%, P< 0.001). Overall, 68% hem/oncs improved their knowledge, competence, and confidence. Further results showed:
• Knowledge regarding the rationale for BCMA-directed therapies for R/R MM: 39% improved (P < 0.001); 225% increase in mastery; 36% decrease uninformed
• Knowledge regarding BCMA-directed bispecific antibodies: 43% improved (P < 0.01); 86% increase in mastery; 77% decrease uninformed
• Knowledge regarding BCMA-directed CAR T-cell therapies: 54% improved (P < 0.01); 100% increase in mastery; 86% decrease uninformed
• Competence related to managing treatment-related adverse events of BCMA-directed antibody conjugates: 45% improved (P=0.058); 23% increase in mastery; 50% decrease uninformed
• Knowledge regarding the value of soluble BCMA as a prognostic biomarker: 61% improved (P < 0.01); 69% increase in mastery; 50% decrease uninformed

Conclusions: This study demonstrates the success of an online CME activity with micro video chapters on improving knowledge, competence, and confidence of hem/oncs related to BCMA-targeted therapies for R/R MM. Additional gaps were identified for future educational targets.